Related Experiment Video
Updated: Jan 26, 2026

Derivation of Thymic Lymphoma T-cell Lines from Atm-/- and p53-/- Mice
Published on: April 3, 2011
ERK-dependent IL-6 positive feedback loop mediates resistance against a combined treatment using danusertib and
Jun Liu1, Junshik Hong1,2,3, Kwang-Sung Ahn4
1Cancer Research Institute, Seoul National University College of Medicine , Seoul , Republic of Korea.
Abstract:
This study was conducted to define the synergistic effect of the PI3K inhibitor BKM120 with the pan-Aurora kinase inhibitor danusertib and the potential mechanism of resistance to the combined inhibitor treatment in Burkitt lymphoma cell lines. The combination of danusertib and BKM120 showed a synergistic effect on Namalwa cells but not on BJAB cells. The combined treatment led to ERK hyperactivation and induced IL-6 secretion in BJAB cells but not in Namalwa cells. A blockade of ERK signaling with trametinib suppressed the combination treatment-induced ERK activation, reduced IL-6 mRNA expression, and downregulated IL-6R mRNA expression, resulting in an improvement in the antitumor effect. We stepwise treated Namalwa cells with both inhibitors using on-and-off treatment cycles and found that Namalwa cells gained chemoresistance by activating the ERK/IL-6 feedback loop, suggesting that the ERK-dependent IL-6 positive feedback loop can compensate for AKT inactivation and is closely associated with adaptive resistance and relapse.
Insights
The PI3K inhibitor BKM120 combined with danusertib showed synergistic effects in Burkitt lymphoma cells. Resistance developed via an ERK/IL-6 feedback loop, highlighting a mechanism for adaptive resistance.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Burkitt lymphoma is an aggressive non-Hodgkin lymphoma.
- Targeting PI3K and Aurora kinases is a therapeutic strategy.
- Understanding resistance mechanisms is crucial for effective treatment.
Purpose of the Study:
- To investigate the synergistic effects of BKM120 and danusertib in Burkitt lymphoma.
- To elucidate the resistance mechanisms to combined PI3K and Aurora kinase inhibition.
Main Methods:
- Cell lines: Namalwa and BJAB (Burkitt lymphoma).
- Inhibitors: BKM120 (PI3K inhibitor), danusertib (pan-Aurora kinase inhibitor), trametinib (ERK inhibitor).
- Assays: Synergy assessment, Western blotting, IL-6 and IL-6R mRNA expression analysis, chemoresistance evaluation.
Main Results:
- Danusertib and BKM120 combination demonstrated synergistic effects in Namalwa cells, but not BJAB cells.
- Combined treatment induced ERK hyperactivation and IL-6 secretion in BJAB cells.
- Trametinib blockade of ERK signaling improved antitumor effects by reducing IL-6 expression.
- Stepwise treatment induced chemoresistance in Namalwa cells via an ERK/IL-6 feedback loop.
Conclusions:
- The ERK/IL-6 feedback loop contributes to adaptive resistance and relapse in Burkitt lymphoma.
- This feedback loop can compensate for AKT inactivation.
- Targeting this loop may overcome resistance to PI3K and Aurora kinase inhibitors.
More Related Videos
Related Concept Videos
Positive and Negative Feedback Loops
Feedback Loops
Cell Signaling Feedback Loops
Negative feedback loops
Most signaling systems have negative feedback loops that can perform different functions such as output limiter, and adaptation.
Output limiter
Upon receiving an input signal, the cellular response rapidly increases until a threshold is reached. Beyond this threshold, a negative feedback loop...
Root Loci for Positive-Feedback Systems
The construction rules for the root locus in positive feedback systems are similar to those in...
Treatment Resistant Cancers
Feedback Inhibition

